What is the current global situation regarding clubfoot?

Key:

  • No evidence of Ponseti

  • Evidence of Ponseti treatment availability (unquantified)

  • Evidence of Ponseti treatment availability (quantified)

  • High income country, or less than 50 expected annual cases

Treatment coverage in countries varies from 1-100%. Globally, coverage in all LMIC in 2023 was 20%.

More about RunFree2030

How does RunFree2030 address clubfoot globally?

Our strategy for global scale up has at its core the Accessible Clubfoot Care and Sustainable Solutions (ACCESS) service delivery model: a replicable framework for delivery of all components of comprehensive clubfoot treatment. ACCESS was developed from the best practices piloted, refined, and adopted by GCI members. This proven approach makes clubfoot services accessible in LMICs for children who need them most through:

  1. Evidence based Ponseti treatment

  2. Programmatic support for comprehensive service delivery across a country or region

  3. An enabling environment  

    The ACCESS model ensures that clubfoot treatment is integrated within health systems and its key elements include early detection and referral (EDR), training, family support, and central coordination. It is adaptable across different environmental contexts and replicable across settings allowing families to find and complete treatment.

    The ACCESS model is implemented while keeping the child at its heart, and partnership and community collaboration is essential to its success.

How do we scale up access to treatment?

RunFree2030 calls scale up to be both vertical-integrating into existing health systems- and horizonal- expanding geographical coverage to reach more children.

Our four cross-cutting strategies are designed to accelerate progress and, when carried out in partnership with governments, civil society organisations, and institutional stakeholders, are achievable and will have a significant impact on tens of thousands of children each year.

What have we achieved so far?

To reach our next milestone of 50% treatment coverage by 2030, we need to approximately double both annual treatment enrolments and budget globally. 

This will need a concerted effort  and collaboration.  We can achieve this by working together!